Table 1 Baseline serum CA19-9 values of subjects in each study

From: Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer

Study description

Dates of enrollment

No. of subjects eligible for this analysis

Median baseline CA19-9 (U cm−3)

Baseline CA19-9, range (U cm−3)

Randomised phase II study of FDR gemcitabine vs standard infusion gemcitabine

1996–1999

25a

3400

98–263 000

Phase I study of FDR gemcitabine+cisplatin

1999–2000

10

3050

136–60 000

Phase II study of FDR gemcitabine+cisplatin

2001–2004

41

2729

129–832 050

Total

 

76

3052

98–832 050

  1. CA19-9=carbohydrate antigen 19-9; FDR=fixed-dose rate infusion of 10 mg m−2 min−1.
  2. aTo maintain as uniform standards of treatment as possible across the three studies, only patients on the FDR arm were included for this analysis.
Back to article page